WordPress database error: [Table 'thehealthcarenews_org_db.wp_ppress_sessions' doesn't exist]
SELECT * FROM wp_ppress_sessions WHERE session_key = '710e8d355f99a02c75c2da06556e47d5'

Gary Romano Exits Passage Bio Startup - The Healthcare News Press "Enter" to skip to content

Gary Romano Exits Passage Bio Startup

Gary Romano has resigned from Passage Bio, a gene therapy startup. On Tuesday, the biotech and its chief medical officer “mutually agreed” to part ways, and Romano did so the same day. Romano’s departure was announced alongside the release of Passage Bio’s chief financial officer, Richard Morris. The two C-suite changes are defined in two separate ways. Morris is resigning on May 30 to seek other opportunities, according to Passage Bio.

Morris said, “Departure was not the result of any disagreement regarding any matter relating to the Company’s operations, financial statements, internal controls, auditors, policies, or practices.” There is no mention in the statement regarding Romano’s departure about whether his departure was due to a dispute.Gary Romano is leaving to seek other opportunities, according to Passage Bio, but unlike Morris, he is going mutually and with immediate effect. While the biotech looks for a permanent successor to Romano, Eliseo Salinas, who joined Passage Bio as chief research and development officer in March, will serve as interim CMO. Salinas has worked as a CMO at several firms, including Elan Pharmaceuticals.

Passage Bio and Romano agreed to a new employment agreement just days before officially announcing Salinas’ nomination. The revised agreement stated that Romano’s employment at Passage Bio would end on Aug. 15, referred to as the “resignation date” in the text. Romano reported to Salinas under the new agreement. Under the previous deal, Romano said to the CEO. Passage Bio and Gary Romano also modified the concept of “fair reason” for resigning to exclude material reductions in his roles, authority, or duties.

Gary Romano has resigned from Passage Bio, a gene therapy startup. On Tuesday, the biotech and its chief medical officer “mutually agreed” to part ways, and Romano did so the same day. Romano’s departure was announced alongside the release of Passage Bio’s chief financial officer, Richard Morris. The two C-suite changes are defined in two separate ways. Morris is resigning on May 30 to seek other opportunities, according to Passage Bio.Morris said, “Departure was not the result of any disagreement regarding any matter relating to the Company’s operations, financial statements, internal controls, auditors, policies, or practices.” There is no mention in the statement regarding Romano’s departure about whether his departure was due to a dispute.

Gary Romano is leaving to seek other opportunities, according to Passage Bio, but unlike Morris, he is going mutually and with immediate effect. While the biotech looks for a permanent successor to Romano, Eliseo Salinas, who joined Passage Bio as chief research and development officer in March, will serve as interim CMO. Salinas has worked as a CMO at several firms, including Elan Pharmaceuticals.Passage Bio and Romano agreed to a new employment agreement just days before officially announcing Salinas’ nomination. The revised agreement stated that Romano’s employment at Passage Bio would end on Aug. 15, referred to as the “resignation date” in the text. Romano reported to Salinas under the new agreement. Under the previous deal, Romano said to the CEO. Passage Bio and Gary Romano also modified the concept of “fair reason” for resigning to exclude material reductions in his roles, authority, or duties.

Be First to Comment

Leave a Reply

Your email address will not be published.